New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
14:01 EDTABTAbbott and Fonterra to form strategic alliance for dairy farming in China
Abbott and Fonterra Co-operative Group today announced the signing of an agreement to develop a proposed dairy farm hub in China. The strategic alliance is subject to Chinese regulatory approval. Both companies will work with Chinese regulators to obtain necessary approvals through the course of the project's development. If approved, Abbott and Fonterra will form a joint venture to invest a combined $300M into the farm hub, which will contain up to five dairy farms and more than 16,000 dairy milking cattle in production, producing up to 160 million liters of milk annually. Pending regulatory approval, the first farm is expected to be completed and producing milk in the first half of 2017 and the remaining farms will commence production in 2018.
News For ABT From The Last 14 Days
Check below for free stories on ABT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTABTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
09:32 EDTABTAbbott initiates ABSORB IV trial
Abbott announced the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold is more cost-effective and offers a higher quality of life than a permanent, metallic drug eluting stent. Unlike a metallic stent, Absorb completely dissolves over time after doing its job. ABSORB IV is designed to enroll approximately 3K people with coronary artery disease, mostly in the U.S. The ABSORB IV trial is designed to confirm these novel findings that treatment with the Absorb device can help provide people with heart disease a higher quality of life after a heart stent procedure. The data from the ABSORB IV trial will be combined with the data from the ABSORB III trial to create a population of more than 5K people studied in the U.S. This data set, which is the largest of its kind for bioresorbable heart devices, provides an opportunity to evaluate the performance of Absorb compared to the current standard of a metallic drug eluting stent across a number of measures, including the broader health economic impact of this innovative therapy.
07:45 EDTABTCardiovascular Research Foundation to hold a conference
Transcatheter Cardiovascular Therapeutics: TCT 2014 to be held in Washington, D.C. on September 13-17 with some presentations being webcasted. Webcast Link
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
September 9, 2014
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 5, 2014
05:46 EDTABTDexCom competition closer after Abbott approval, says Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use